References

Ellansé

* Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomised, controlled clinical trial. Dermatol Surg. 2013;39 (3 Pt 1):457-63. Journal of Cosmetic Dermatology.

** Expected longevity in-vivo based on extrapolation of clinical data from –S (1 year) and –M (2 years) accepted PCL degradation behaviour.

Sinclair Network

At Sinclair we strive to provide the highest standards of training and ongoing support, working in partnership with our physician customers to deliver patients unparalleled clinical results and industry leading safety standards.

Sinclair announces $5 million investment by EW Healthcare Partners via convertible loan

Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, is pleased to announce a $5 million investment in the Group via the issue of a $5.0 million convertible loan to EW Healthcare Partners (“EW”)

Sinclair and ThermiGen terminate US distribution agreement

Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, announces that its contract with ThermiGen LLC (“Thermi”), an Almirall SA company, for the sale and distribution of Silhouette InstaLift™, Silhouette Refine™ and Silhouette Lift®